Venture Certified
| 혁신성장유형 | 2023-06-07 ~ 2026-06-06 | 20230607030039 | 2023-06-07 |
Revenue CAGR +395.1%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 2.2B | 0.4B | 0.0B |
| Operating Profit | -2.3B | -1.7B | -0.6B |
| Net Profit | -1.9B | -1.7B | -0.6B |
| Total Assets | 2.8B | 4.5B | 4.4B |
| Total Liabilities | 0.8B | 0.6B | 0.0B |
| Total Equity | 2.0B | 3.9B | 4.4B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -2B
3 Consecutive Years of Net Loss
Debt Ratio Surge (+23pp YoY)
▲ 890.1%
▼ 93.8%
▲ 73.3%
▲ 391.1%
▼ 240.4%
| Name | Position | Role |
|---|---|---|
| 노영호 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "서울특별시 서초구",
"ceo_name": "노영호",
"certificate": [
{
"cert_number": "20230607030039",
"changes": "",
"disclosure_date": "2023-06-07",
"first_cert_date": "2023-06-07",
"no": "1",
"type": "혁신성장유형",
"valid_period": "2023-06-07 ~ 2026-06-06"
}
],
"company_name": "(주)이립바이오",
"corp_no": "110111-*******",
"financials": {
"2022": {
"capital_stock": 500000000,
"cost_of_sales": 0,
"current_assets": 439487000,
"current_liabilities": 3034000,
"gross_profit": 0,
"net_income": -63197000,
"net_income_bs": -63197000,
"non_current_assets": 350000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 223000,
"operating_profit": -63420000,
"revenue": 0,
"sga_expenses": 63420000,
"total_assets": 439837000,
"total_equity": 436803000,
"total_liabilities": 3034000
},
"2023": {
"capital_stock": 616000000,
"cost_of_sales": 41680000,
"current_assets": 443395000,
"current_liabilities": 58914000,
"gross_profit": 2384000,
"net_income": -166648000,
"net_income_bs": -166648000,
"non_current_assets": 10000000,
"non_current_liabilities": 0,
"non_operating_expenses": 5000,
"non_operating_income": 6406000,
"operating_profit": -173049000,
"revenue": 44064000,
"sga_expenses": 175433000,
"total_assets": 453395000,
"total_equity": 394481000,
"total_liabilities": 58914000
},
"2024": {
"capital_stock": 616000000,
"cost_of_sales": 220415000,
"current_assets": 267748000,
"current_liabilities": 77025000,
"gross_profit": -2273000,
"net_income": -193758000,
"net_income_bs": -193758000,
"non_current_assets": 10000000,
"non_current_liabilities": 0,
"non_operating_expenses": 1000,
"non_operating_income": 35337000,
"operating_profit": -229094000,
"revenue": 218142000,
"sga_expenses": 226821000,
"total_assets": 277748000,
"total_equity": 200723000,
"total_liabilities": 77025000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "아이스플랜트 연구 개발",
"phone": "010-5660-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | Public Data | Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| G2B Procurement | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |